Breast Cancer Res Treat 2011, 127:429–438.PubMedCrossRef

18. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, RAD001 Ericson SG, Perez EA: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77–85.PubMedCrossRef 19. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010, 21:2188–2194.PubMedCrossRef 20. Reid DM: Prevention of osteoporosis after breast cancer. Maturitas 2009, 64:4–8.PubMedCrossRef 21. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S: The influence of family history and histological stratification on breast cancer risk in women

with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 2011, 137:1053–1060.PubMedCrossRef 22. Zhou WB, Ding Q, Chen L, Liu XA, Wang S: Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat 2011, 128:625–631.PubMedCrossRef 23. Liu X, Wang Z, Yu J, Lei G, Wang S: Three polymorphisms in interleukin-1beta gene and risk for breast cancer:

a meta-analysis. Breast Cancer Res Treat 2010, 124:821–825.PubMedCrossRef see more 24. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820–826.PubMed 25. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719–748.PubMed 26. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177–188.PubMedCrossRef 27. Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D: Randomized trial of adjuvant zoledronic 2-hydroxyphytanoyl-CoA lyase acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer 2010, 10:471–476.PubMedCrossRef 28. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J: Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009, 7:101–107.PubMed 29. Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY: Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06–01). Breast Cancer Res Treat 2011, 125:99–106.

Bovicin HC5 stock solutions (1 mg ml-1 in PBS (10 mM, pH 7.2)) were stored at −20°C until use. Protein concentration was determined using a bicinchoninic acid protein assay (Pierce Chemical Corp., Bonn, Germany), with bovine serum albumin as the standard. Experimental animals The BALB/c mice used in this study were housed in an animal facility at the Universidade Federal de Viçosa, according to standards and guidelines as set forth in the Animal Selleckchem MK 2206 Welfare Legislation, the Guide for the Care and Use of Laboratory

Animals, the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the National Council for Animal Experimentation Control (CONCEA), following approval by the Institutional Animal Care and Use Committee

(IACUC) of the Universidade Federal de Viçosa under the protocol number Dabrafenib chemical structure CEUA/UFV 97/2011. Five-week-old female BALB/c mice were randomly divided into three experimental groups: Group 1, untreated mice (negative control, NC group); Group 2, mice given purified bovicin HC5 (Bov group); Group 3, mice given ovalbumin (Sigma Chemicals Co., St. Louis, MO, 99% of purity) (positive control, PC group). Two independent experiments were performed and a total number of eight animals were used per experimental group. The sensitization procedure was developed based on previously established protocols [18]. Mice from the Bov group were subcutaneously sensitized with bovicin HC5 (4 μg/g animal weight/day or approximately 70 μg/animal [35]), while animals from the PC group were sensitized with ovalbumin (100 μl of a 1 mg ml-1 stock solution in sterile ultrapure water, or 100 μg OVA/animal). Aluminum hydroxide was used as adjuvant (50 μl; 20 mg ml-1 stock solution in sterile saline) at the first sensitization (day 0). After three weeks, each mouse group was subcutaneously boosted (without the use of adjuvant)

with the respective substances Cyclin-dependent kinase 3 (second sensitization, day 21). The NC group was sensitized with sterile PBS (10 mM, pH 7.2), using the same procedure described above. PBS, bovicin HC5 or ovalbumin (100 μl) were administered without adjuvant to the NC, Bov and PC groups, respectively, by daily gavages (18-gauge stainless steel feeding needles). Oral administration started one week after the second sensitization (day 28) and continued for 30 days uninterruptedly (day 58). The mice were weekly weighted and behavior, general appearance and adverse reactions were monitored daily. Gut permeability The gut permeability was determined by the uptake of β-lactoglobulin (β-LG) following challenge ([36], with modifications]). At the end of the trial period (day 58), the animals of the NC, Bov and PC groups, were orally challenged with 200 μl of the respective samples (PBS, bovicin HC5 or ovalbumin).